[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-405228-105":59,"doc-detail-405228-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","use-of-oral-prep-for-hiv-prevention-key-points-for-clinicians","Use of Oral PrEP for HIV Prevention - Key Points for Clinicians","","Clinician-focused guidance on oral HIV pre-exposure prophylaxis (PrEP), covering decision-making before initiation and safe, effective ongoing management. The material explains how daily antiretroviral therapy prevents HIV replication, outlines required baseline HIV and STI/HBV/HCV evaluations, and emphasizes monitoring for drug–drug interactions and side effects. It also details protection timelines by exposure type, recommended condom use, follow-up testing intervals, interruption and restart testing, and special population considerations including MSM 2-1-1 dosing, perinatal use, and adolescent confidentiality.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/use-of-oral-prep-for-hiv-prevention-key-points-for-clinicians/405228/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/use-of-oral-prep-for-hiv-prevention-key-points-for-clinicians/405228.png","ImageObject",300,407,{"name":92,"@type":93},"Aran","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-07","2026-09-28",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Who should be prescribed oral PrEP, and what eligibility requirements are emphasized?","Question",{"text":113,"@type":114},"Oral PrEP should be prescribed to patients experiencing ongoing HIV risk who are clinically eligible and who request it. It should be discussed in clinical visits with sexually active individuals and people who inject IV drugs.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What baseline tests are recommended before starting oral PrEP therapy?",{"text":118,"@type":114},"Baseline testing includes a combination HIV antibody/antigen assay (with HIV RNA if acute infection is suspected), estimated creatinine clearance, syphilis testing, and genital and non-genital gonorrhea/chlamydia testing by NAAT. Hepatitis A, B, and C serology is also recommended, with a lipid panel if using F/TAF.",{"name":120,"@type":111,"acceptedAnswer":121},"How should oral PrEP be managed when stopping or restarting, and what testing is needed?",{"text":122,"@type":114},"After cessation, PrEP should be continued for 7 days following the last at-risk exposure. If PrEP was stopped for 7 or more consecutive days, a combined HIV antibody and antigen test is recommended prior to restarting.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},405228,1790804020,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":14,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":24,"preview_page_count":4},137455076865,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","MidAtlantic AIDS Education and Training Center Use of Oral PrEP for HIV Prevention  \nPrEP (pre-exposure prophylaxis): Daily use of daily antiretroviral medication for HIV prevention  \nKey Points for Clinicians: Prior to Initiation  \n• PrEP is a highly effective biomedical prevention option for patients experiencing ongoing HIV risk and should be prescribed to any patient who requests it and is clinically eligible.  \n• Taking daily oral PrEP medication prevents HIV from replicating in the body, thereby preventing infection  \n• PrEP for HIV prevention should be discussed in clinical visits with all sexually active individuals and persons who inject IV drugs.  \n• Prior to initiation of PrEP, assessment for signs and symptoms of acute HIV infection is essential for discussion of PrEP for HIV  \nprevention (CDC HIV PrEP Guidelines 2021, p 29)  \n• Prior to initiating PrEP, a clinician should assess for drug-drug  \ninteractions and discuss potential side effects (CDC HIV PrEP Guidelines 2021-on page 39-table 4)  \n• Use of PrEP medications can attenuate or delay HIV seroconversion diagnostic assays (CDC HIV PrEP Guidelines 2021-p 29-31 figure 4a-4b)  \n• While on PrEP, condoms are still recommended to reduce risk of other STIs (CDC HIV PrEP Guidelines 2021-on page 26)  \n• Sexually transmitted disease testing and treatment is recommended every 3-months as clinically appropriate (CDC HIV PrEP Guidelines 2021, p. 31-32)  \n• Include discussion about safer sex practices and contraception with patients while they are on PrEP  \n• F/TAF is a recommended option for sexually active persons at risk through receptive vaginal sex (especially those at risk for kidney dysfunction, osteopenia, or osteoporosis) (CDC HIV PrEP Guidelines 2021, p. 37-38, IAS HIV Treatment Guidelines 2021, p. E11)  \nOral PrEP associated baseline HIV testing and other testing needed prior  \nto the initiation of PrEP therapy (CDC HIV PrEP Guidelines 2021, p.15-16):  \n• Combination HIV antibody/antigen assay (HIV RNA assay if clinical suspicion of acute HIV)  \n• Estimated creatinine clearance  \n• Syphilis testing  \n• Genital and non-genital gonorrhea and chlamydia testing by nucleic acid amplification test (NAAT)  \n• Hepatitis A, B and C serology  \n• Lipid panel (if using F/TAF) (CDC HIV PrEP Guidelines 2021-pages 44)  \n*Modified from Nunn, et al. Defining the HIV pre-exposure prophylaxis care continuum, AIDS 2017, 31(5): 731-734  \nKey Points for Clinicians: Ongoing Management  \nPrEP works  \n• After contact with the virus, tenofovir and emtricitabine block the enzyme needed by the virus to replicate  \n• PrEP (F/TDF) reaches maximum protection from HIV for receptive anal sex (bottoming) at about 7 days of daily use.  \n• PrEP reaches maximum protection for receptive vaginal sex and injection drug use at about 20 days of daily use.  \n• No data are available for insertive anal sex (topping), insertive vaginal sex, or for F/TAF use (CDC HIV PrEP Guidelines 2021, p 42-43)  \nPrEP Interruption  \n• At cessation, PrEP should be continued for 7 days after the last at-risk exposure (CDC HIV PrEP Guidelines 2021, p. 46-47).  \n• For individuals who have stopped PrEP for 7 or more consecutive days, the combined HIV antibody and antigen testis recommended prior torestarting PrEP (IAS HIV Treatment Guidelines 2021, p. 1662).  \n• An abrupt discontinuation of oral PrEP in an individual with chronic active Hepatitis B infection may be at a higher risk for hepatitis flares (CDC HIV PrEP Guidelines 2021, p. 47).  \n• Patients who wish to discontinue PrEP should have a follow-up conversation about risk vs benefits with their clinician, as they are at a higher risk of HIV acquisition (IASHIV Treatment Guidelines 2021).  \nMIDATLANTIC AIDS EDUCATION AND TRAINING CENTER  \nUniversity of Pittsburgh, School of Public Health  \nDepartment of Infectious Disease and Microbiology  \n[www.maaetc.org](www.maaetc.org)  \nHRSA, HIV/AIDS Bureau, Office of Program Support  \nGrant No. U1OHA29295  \nLast Modified: July 202","cbCaisse2qKzgAfn","https://ap.wps.com/l/cbCaisse2qKzgAfn","pdf",143887,"English","# Key Points for Clinicians: Prior to Initiation\n## Oral PrEP associated baseline HIV testing and other testing needed prior to initiation\n# Key Points for Clinicians: Ongoing Management\n## PrEP works\n## PrEP Interruption\n# Special Population Considerations\n## Oral PrEP-associated testing with recent/ongoing therapy\n# References","[{\"question\":\"Who should be prescribed oral PrEP, and what eligibility requirements are emphasized?\",\"answer\":\"Oral PrEP should be prescribed to patients experiencing ongoing HIV risk who are clinically eligible and who request it. It should be discussed in clinical visits with sexually active individuals and people who inject IV drugs.\"},{\"question\":\"What baseline tests are recommended before starting oral PrEP therapy?\",\"answer\":\"Baseline testing includes a combination HIV antibody/antigen assay (with HIV RNA if acute infection is suspected), estimated creatinine clearance, syphilis testing, and genital and non-genital gonorrhea/chlamydia testing by NAAT. Hepatitis A, B, and C serology is also recommended, with a lipid panel if using F/TAF.\"},{\"question\":\"How should oral PrEP be managed when stopping or restarting, and what testing is needed?\",\"answer\":\"After cessation, PrEP should be continued for 7 days following the last at-risk exposure. If PrEP was stopped for 7 or more consecutive days, a combined HIV antibody and antigen test is recommended prior to restarting.\"}]","Use of Oral PrEP for HIV Prevention - Key Points for Clinicians | PDF",1790555475]